Provectus Biopharmaceuticals, Inc. (OTCMKTS:PVCT) Short Interest Update

Provectus Biopharmaceuticals, Inc. (OTCMKTS:PVCT) saw a significant increase in short interest in the month of June. As of June 15th, there was short interest totaling 802,784 shares, an increase of 41,110.7% from the May 31st total of 1,948 shares. Approximately 0.2% of the shares of the company are sold short. Based on an average daily trading volume, of 182,658 shares, the short-interest ratio is presently 4.4 days.

Provectus Biopharmaceuticals Price Performance

OTCMKTS PVCT traded up $0.00 on Thursday, reaching $0.07. The stock had a trading volume of 60,818 shares, compared to its average volume of 255,105. Provectus Biopharmaceuticals has a 12-month low of $0.04 and a 12-month high of $0.10. The business’s 50-day moving average price is $0.06 and its 200 day moving average price is $0.06.

About Provectus Biopharmaceuticals

Provectus Biopharmaceuticals, Inc is a U.S.-based clinical-stage biopharmaceutical company focused on the development and commercialization of immuno-oncology and tumor ablation therapies. Headquartered in Knoxville, Tennessee, the company’s lead investigational product is PV-10, a proprietary formulation of Rose Bengal disodium for intralesional injection. PV-10 is designed to selectively ablate tumor cells while stimulating a systemic immune response against cancerous lesions.

PV-10 has been evaluated in multiple clinical trials across a range of solid tumors, with key studies conducted in melanoma, hepatocellular carcinoma and other refractory cancers.